surmount-1 trial tirzepatide non-diabetic obesity weight loss for Obesity: Highlights from the Tirzepatide for Obesity Treatment and

Long-term studies and clinical trials indicate that patients who continue treatment with these medications, along with adherence to recommended lifestyle changes, are more likely to maintain significant weight loss compared to those who discontinue the medication

Because GIP and GLP-1 do overlapping but distinct things in the body, and the combination produces effects that neither achieves alone

Adipose tissue lipolysis contributes to about 59% of stored hepatic fatty acids, while DNL and dietary intake contribute 26% and 15%, respectively

GLP-1 receptor agonists mimic this natural hormone to: Slow down gastric emptying Increase insulin secretion Decrease glucagon release Reduce appetite and food intake These effects lead to lower blood sugar levels and gradual, sustained weight loss

Lysate was rotated at 4 C overnight in a final concentration of 0.2 N H 2 SO 4

Wegovy stimulates receptors of a hormone called Glucagon Like Peptide 1 or GLP-1